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Abstract
Objective—To investigate the relationship of cerebrovascular risk factors (CVRFs), endothelial
function, carotid artery intima medial thickness (IMT), and neuropsychological performance in a
sample of 198 middle-aged and older individuals with major depressive disorder (MDD).
Neuropsychological deficits are common among adults with MDD, particularly among those with
CVRFs and potentially persons with subclinical vascular disease.
Methods—CVRFs were indexed by the Framingham Stroke Risk Profile (FSRP) and serum
cholesterol levels obtained by medical history and physical examination. Patients completed a
neuropsychological test battery including measures of executive functioning, working memory,
and verbal recall. Vascular function was indexed by carotid artery IMT and brachial artery flow
mediated dilation (FMD). Hierarchical multiple regression analyses were used to investigate the
association between CVRFs, vascular disease, and neurocognitive performance.
Results—Greater FSRP scores were associated with poorer executive functioning (b = −0.86; p
= .041) and working memory (b = −0.90; p = .024). Lower high-density lipoprotein levels also
were associated with poorer executive functioning (b = 1.03; p = .035). Higher IMT (b = −0.83; p
= .028) and lower FMD (b = 1.29; p = .032) were associated with poorer executive functioning
after controlling for CVRFs. Lower FMD was also associated with poorer working memory (b =
1.58; p = .015).
Conclusions—Greater CVRFs were associated with poorer neuropsychological performance.
Vascular dysfunction also was associated with neuropsychological decrements independent of
traditional CVRFs.
Keywords
cerebrovascular risk; vascular disease; neuropsychological performance; depression; endothelial
function
INTRODUCTION
Cerebrovascular disease is a major health burden in the United States (1) and is associated
with an increased incidence of cognitive impairment (2). Previous studies have shown that
greater levels of cerebrovascular risk factors (CVRFs), such as hypertension, diabetes,
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smoking (3), and increased serum cholesterol levels are associated with poorer
neuropsychological functioning (4) as well as increased rates of cognitive decline (5).
Furthermore, a growing body of evidence indicates that neuropsychological deficits may be
predictive of incident cardiovascular disease and stroke (6) as well as dementia (7) and may
therefore represent a neurobehavioral index of cerebrovascular risk.
Recent studies have shown that psychosocial factors, particularly depression, may be
associated with an increased risk of cerebrovascular disease (8). The relationship between
CVRFs and neuropsychological performance is particularly important for individuals with
major depressive disorder (MDD) because both CVRFs (9–13) and neuropsychological
deficits (14,15) are prevalent in this population. Furthermore, CVRFs have been associated
with an increased risk for the development of mild cognitive impairment (16), a variety of
neuroanatomical abnormalities (17–20), and an increased incidence of vascular depression
(21). Although CVRFs have been reported to be associated with poorer cognitive
performance among individuals with late-onset depression (21), the relationship between
CVRFs and neuropsychological functioning among individuals with MDD without
significant medical comorbidities remains unclear.
A growing body of evidence also indicates that vascular functioning may be related to
neuropsychological performance (22,23) and may be compromised among individuals with
MDD (24,25). Although CVRFs are associated with poorer vascular functioning (26), the
extent to which diminished vascular functioning is associated with impairments in
neuropsychological performance independent of CVRFs has not been examined.
Furthermore, although individual CVRFs, such as increased systolic blood pressure, have
been shown to be related to incident cerebrovascular disease (27), few studies have
examined the relationship between CVRFs and neuropsychological performance in a graded,
dose-response fashion (5,28). Similarly, recent studies demonstrating a relationship between
vascular functioning and neuropsychological performance functioning have relied on
structural indicators of systemic vascular dysfunction such as carotid plaque (29) and
increased carotid artery intima medial thickness (IMT) (22,23), but have not examined
vascular function in the context of multiple CVRFs.
METHODS
Experimental Design
The data reported in this study were obtained from a larger trial that examined the effects of
exercise and antidepressant medication in the treatment of middle-aged and older individuals
with MDD based on clinician-diagnosed Diagnostic and Statistics Manual 4th edition
(DSM-IV) criteria (30). Exclusion criteria were as follows: a) a primary psychiatric
diagnosis other than MDD; b) medical contraindications preventing participation in either
the exercise or medication arm of the study; and c) current antidepressant use. Participants
were recruited from October 2000 to September 2005. The study protocol was approved by
a Duke Institutional Review Board.
Cerebrovascular Risk Factors
Framingham Stroke Risk Profile (FSRP)—CVRF scores were determined at the
baseline screening and physical examination using the FSRP, a risk assessment tool used to
assess the 10-year incidence of stroke (31). Risk factors used to assess stroke risk include
systolic blood pressure, use of antihypertensive therapy, diabetes mellitus, cigarette
smoking, cardiovascular disease, and atrial fibrillation (31,32). Because age served as a
covariate in our final analyses, it was not included in calculating FSRP scores. Furthermore,
left ventricular hypertrophy, a component of the original FSRP score, was not used in the
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current analysis because this information was not routinely obtained. Participants with a
prior history of stroke (n = 4) were excluded from the final analyses.
Serum Cholesterol
High-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol were
measured enzymatically (LabCorp, Research Triangle Park, NC). HDL cholesterol was
estimated by assay of the supernatant remaining after precipitation of serum LDL with
dextran sulfate plus magnesium chloride. Participants fasted for 12 hours before this
assessment.
Measures of Subclinical Vascular Disease
Intima Medial Thickness (IMT) in Carotid Arteries—Carotid artery IMT was
assessed by a high-resolution B-mode ultrasound vascular imaging system (Acuson Aspen,
Mountain View, CA) with a 10-Mhz linear array transducer. Ultrasound examinations of the
far wall of the left and right common carotid arteries (CCAs) were used to acquire
longitudinal images spanning 2 cm proximal to the carotid bulb. IMT of the far wall of the
left and right CCAs was measured over a 1-cm segment using edge detection software
(Carotid Analyzer 5.0.5, Medical Imaging Applications LLC, Iowa City, IA). Far wall
measurements only were used as near wall measurements have been shown to have limited
reliability (33).
Flow Mediated Dilation (FMD) and Nitroglycerin Mediated Dilation (GTN-D) of
the Brachial Artery—FMD and GTN-D of the brachial artery were assessed in the
morning, after overnight fasting. Participants were instructed to avoid use of vasoactive
medications (a list was provided to participants) from midnight until after the FMD
assessments were completed. Longitudinal B-mode ultrasound images of the brachial artery,
4 to 6 cm proximal to the antecubital crease, were obtained using an ultrasound platform
(Aspen, Mountain View, CA) with a 10-MHz linear array transducer. Images were obtained
under the following conditions: a) after 10 minutes of supine relaxation; b) during reactive
hyperemia, induced after inflation for 5 minutes to suprasystolic pressure (~200 mm Hg) of
a pneumatic occlusion cuff placed around the forearm; c) after an additional 10 minutes
relaxation period in the supine position; and d) after the administration of 400 μg sublingual
glyceryl trinitrate (GTN) spray. End-diastolic images were stored to a magnetic-optical disk
and arterial diameters were measured as the distance between the proximal and distal arterial
wall intima media interfaces, using PC-based software (Brachial Analyzer Version 4.0,
Medical Imaging Applications LLC, Iowa City, IA).
Peak hyperemic flow was assessed by Doppler velocity measurement during the first 10
seconds post deflation of the occlusion cuff, and hyperemic flow response was defined as
percent change in flow relative to resting baseline. Peak FMD response was assessed from
10 to 120 seconds post deflation of the cuff, with peak arterial diameter quantified using
polynomial curve fitting. FMD was defined as the maximum percent change in arterial
diameter relative to resting baseline. GTN-D was defined as peak percent change in arterial
diameter assessed 3 to 5 minutes after the administration of GTN.
Assessment of Cognitive Functioning
All participants underwent a standard neuropsychological test battery to assess performance
in multiple domains of cognitive functioning. Tests were selected based on the brevity of
their administration, availability of normative data, and the availability of multiple forms for
repeat testing. The following instruments were administered individually by a trained
research assistant:
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• Weschler Memory Scale Logical Memory Subset (34). The Logical Memory
Subtest requires participants to repeat a story read to them aloud by the examiner.
Immediate recall is evaluated using a verbatim scoring procedure. This test is used
to assess discourse memory and oral language comprehension.
• Controlled Oral Word Association Test (COWAT) (35). The COWAT requires
participants to generate as many words as possible beginning with different letters
of the alphabet in a 1-minute period. The letters C, F, L and P, R, W were used in
the current study. The COWAT is designed to assess working memory and verbal
fluency.
• Wechsler Adult Intelligence Scale-Revised Digit Symbol Substitution Test (DSST)
(36). The DSST is a measure of executive functioning in which participants are
asked to draw symbols that match one of 10 digits copied from a key. Scores on
this task are the number of correct symbols drawn in a 90-second time period.
• Ruff 2 and 7 Test (37). The Ruff 2 and 7 Test is a paper-and-pencil test that
assesses perseveration, a component of executive functioning. Participants are
required to cross out all instances of the numbers 2 and 7 under a) the first
condition in which they are embedded among other digits and b) the second
condition in which they are embedded among letters. Stimuli are presented in
consecutive blocks of three lines (each line consisting of 10 targets and 40
distracters) representing each condition with a 15-second time limit per block, in
pseudorandom order. The score is the total number of correct cancellations within a
5-minute time period.
• Verbal Paired Associates (34). The Verbal Paired Associates Test assesses working
memory by presenting participants with a list of eight word pairs, half of which had
high association (e.g., baby-cries) and the remaining half which had low
association (e.g., school-grocery). After the list has been read aloud, participants
are presented with one word from each pair and are asked to name a corresponding
word from the original list. The list of words is then repeated on two subsequent
trials and the recall process is repeated. Scores of high association recall and low
association recall are calculated.
• Weschler Digit Span (36). The Digit Span Test (DST) assesses attention and
working memory. In this test, participants are asked to recall a list of consecutive
numbers that become sequentially longer as the participants answer more trials
correctly. In the first trial, participants are asked to recall the numbers in the same
order in which they were presented. In the second trial, participants are asked to
recall the numbers in the reverse order from which they were presented.
• Stroop Color and Word Test (38). The standardized version of the Stroop test used
in the current study consists of three sections: word, color, and color-word. In each
section, participants are presented with a page consisting of five columns, each
with 20 items for a total of 100 items per page. Within each section, the score is the
total number of words read aloud in 45 seconds. The word section requires
participants to read a list of color words (“RED,” “BLUE,” and “GREEN”) as
quickly as possible. For the color section, participants name aloud the color of a
series of colored bars printed on the page. The color-word list is similar to the color
list in that the task is to name the color in which each item is printed. The items in
this list, however, are color names, in which the names of the items differ from the
colors in which they are printed (e.g., the word RED is printed in blue ink). The
word and color tests are believed to measure processing speed, whereas the color-
word section (also known as the “interference” section) is believed to measure
selective attention, a component of executive functioning.
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• Animal Word Fluency Test (39). The Animal Fluency Test is a test of semantic
fluency and working memory in which the participant is instructed to generate
words from a specified category (in this case, animals). The score is the total
number of animals generated in a 60-second time period.
• Trail Making Test Part A (TMT-A) (40). The TMT-A requires participants to draw
consecutive lines between the numbers 1 through 25 as fast as possible. The score
is the time (in seconds) required for completion and is believed to measure
processing speed and selective attention.
• Trail Making Test Part B (TMT-B) (40). The TMT-B requires participants to draw
consecutive lines alternating back and forth between the numbers 1 and 13 and the
letters A through L. The score is the time (in seconds) required for completion and
is believed to measure visual search and attentional processes associated with
executive functioning.
Assessment of Depression
Diagnostic Interview Schedule—The presence of MDD was determined by a trained
clinical psychologist using the Diagnostic Interview Schedule (41). All participants met the
criteria for MDD based on DSM-IV (42).
Hamilton Rating Scale for Depression (HRSD)—Depression severity was assessed
using the HRSD (43), a 17-item clinical rating scale that assesses the severity of depressive
symptoms such as changes in appetite, sleep, and depressed mood.
Statistical Analysis
Data Reduction—To minimize the number of statistical tests in the present analysis, we
used principle axis factor analysis to combine information from the 10 individual
neuropsychological tests into three cognitive domain scores. A Scree test was used to
determine the total number of factors retained for analysis. A minimum loading of 0.40 was
required and Promax rotation was used. Based on these results, we created unit-weighted
composite scores by standardizing the individual neuropsychological test scores and then
summing all subtests relevant to a given domain. These composites were then used as the
criterion variable in the regression models described below. TMT-A and TMT-B and the
COWAT were log-transformed before analysis.
Data Analysis—A separate hierarchical multiple regression analysis was conducted for
each cognitive domain to determine if vascular functioning was associated with
neuropsychological performance independently of CVRFs. For each model, a hierarchical
approach was used in which variables were entered in blocks: a) background characteristics
(age, education, depression severity, and baseline arterial diameter (FMD analyses only))
and b) CVRFs (FSRP and lipids). After these blocks were entered, we entered IMT alone
and then FMD alone (without IMT) to examine the contribution of each variable in the
presence of the first two blocks. As a final step, IMT and FMD were entered together in
addition to the first two blocks. Multiple imputation based on the parametric maximum
likelihood regression was used to account for missing data. Model assumptions of additivity,
linearity, and distribution of residuals were evaluated and found to be adequate before
analysis. Regression coefficients were scaled using the interquartile range of the predictor
variable. This scaling allows the coefficient to be interpreted as comparing a “typical”
person in the middle of the upper half of the predictor distribution with a “typical” person in
the middle of the lower half of the predictor distribution.
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Data from 198 (98%) of the original 202 patients were used in the final analysis, including
150 women (76%) and 48 men (24%). Background characteristics for the sample are
presented in Table 1. The mean age for the overall sample was 51.6 ± 7.5 (standard
deviation) years. The majority of patients were Caucasian and college-educated. Most
participants were either overweight or obese and many were current or former smokers. On
average, participants had mildly elevated blood pressure and approximately one quarter of
the sample reported regular use of antihypertensive medications. Lipid levels were
increased, but relatively few participants (8.6%) reported regular use of lipid-lowering
medications. Most participants were free from any cardiac condition with only four
reporting a history of atrial fibrillation and two patients with a documented history of
coronary artery disease. The CVRF score in the current sample was 5.4 ± 3.2, indicating
participants had relatively low levels of stroke risk. Most participants were mildly to
moderately depressed (Ham-D score = 16.7 ± 4.3).
Neuropsychological Functioning
Neuropsychological characteristics of the study sample are presented in Table 2. Results
from the common factor analysis demonstrated three factors from the neuropsychological
battery corresponding to three cognitive domains, which we have labeled executive
functioning (Stroop interference, Digit Symbol Substitution, Ruff 2 and 7 Test, and Trail
Making Tests), working memory (Controlled Oral Word Association Task, Animal Naming,
TMT-B, and DST), and verbal recall (Weschler Logical Memory Subset and the Verbal
Paired Associates Tests). The correlations between individual subtests and composite
neuropsychological test scores are presented in Table 3.
Relationship Between CVRFs and Neuropsychological Functioning
Greater FSRP scores were associated with lower executive functioning (b = −0.86; p = .041)
and working memory (b = −0.90; p = .024); the association with verbal recall was smaller in
magnitude and not statistically significant (b = −0.22; p = .283). Higher levels of HDL-C
were associated with better executive functioning scores (b = 1.03; p = .035); the association
with working memory was smaller and not statistically significant (b = 0.78; p = .119),
whereas the association with verbal recall was small and not statistically significant (b =
−0.01; p = .948).
Hierarchical Regression
Results from the hierarchical regression models of executive functioning and working
memory are presented in Tables 4 and 5, respectively. As shown in Table 4, the inclusion of
CVRFs significantly improved the fit of the executive functioning model (adjusted R2
change = 4%; p = .011) and marginally improved our model of working memory (adjusted
R2 change = 2.1%; p = .065). IMT was significantly related to executive functioning after
controlling for CVRFs (p = .032) (Figure 1), but was not significantly related to working
memory (p = .28). FMD also significantly improved the fit of the executive functioning
(adjusted R2 change = 2.6%; p = .032) (Figure 2) and working memory (adjusted R2 change
= 2.4%; p = .015) (Figure 3) models. When IMT and FMD were entered simultaneously into
our model of executive functioning, FMD (p = .033) remained a significant predictor
although the relationship between IMT and executive functioning was attenuated (p = .11).
Similarly, after controlling for CVRFs and IMT, GTN-D significantly improved the fit of
the executive functioning model (adjusted R2 change = 2.0%; b = 1.52; p = .047), but was
not significantly related to working memory (b = 0.93; p = .294).
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CVRFs did not improve the fit of the verbal recall model. Similarly, neither IMT (b = 0.16;
p = .414) nor FMD (b = 0.33; p = .273) was associated with the verbal recall composite
score in the presence of CVRFs.
DISCUSSION
Results of this investigation indicate that higher levels of cerebrovascular risk are associated
with poorer neuropsychological functioning among adults with MDD. We found that greater
levels of CVRFs, including diabetes, hypertension, and smoking, were associated with
poorer performance on measures of executive functioning and working memory. Higher
levels of HDL cholesterol, in contrast, were actually associated with better executive
functioning. Three noninvasive measures of presymptomatic vascular dysfunction—IMT,
FMD, and GTN-D—were also associated with decrements in neuropsychological
performance. Increasing levels of IMT, an index of subclinical atherosclerosis, were
associated with poorer executive functioning but were not associated with working memory
after controlling for CVRFs. Poorer endothelial function, indexed by lower FMD, was
associated with poorer executive functioning and working memory after controlling for both
CVRFs and IMT. Similarly, poorer overall vascular response, indexed by lower GTN-D,
was associated with poorer executive functioning after controlling for CVRFs and IMT,
although GTN-D was not significantly related to working memory.
Previous population studies have shown that greater levels of CVRFs may be associated
with a poorer cognitive functioning (44). In a sample of approximately 11,000 individuals
from the Atherosclerotic Risk in Communities study, Knopman and colleagues found that
the presence of diabetes and hypertension at baseline testing were associated with more
rapid cognitive decline (44). Similarly, Elias and colleagues (3) found that both hypertension
and diabetes were associated with poorer neuropsychological performance on a variety of
measures, most notably memory. Furthermore, Elias and colleagues (5) found that CVRFs,
measured using the FSRP, were associated with poorer performance across a range of
neuropsychological tests, including measures of visual-spatial and executive functioning.
More recently, Sheline and colleagues (28) found that higher levels of CVRFs were
associated with poorer processing speed, memory, and executive functioning in a study of
individuals with late-onset depression.
Neuropsychological deficits (14,15) and CVRFs (9 –13) are common among individuals
with MDD and are associated with cognitive impairment in the general population (45,46).
Individuals with MDD have been shown to exhibit neuropsychological deficits over a broad
range of cognitive domains (47– 49), particularly on tasks associated with frontal lobe
activity, such as executive functioning (9,10). Deficits in executive functioning have also
been demonstrated among individuals with vascular depression, a late-onset subtype of
MDD that is particularly resistant to conventional therapeutic techniques (9,28) and is
associated with ischemic damage to the prefrontal-subcortical loops that control executive
functions (50,51).
The existing literature on the relationship between serum cholesterol and
neuropsychological performance has yielded mixed results. Elias and colleagues found that
higher levels of total cholesterol were associated with better neuropsychological
performance in the Framingham Heart Study (52). Interestingly, Muldoon and colleagues
also reported a positive relationship between total cholesterol and fluid intelligence levels,
whereas higher cholesterol was associated with poorer scores on measures of crystallized
intelligence (4). Generally, previous studies among older individuals have noted a protective
effect of elevated HDL level (53), although the relationship between LDL and cognitive
functioning is less clear (52,54). Discrepant findings may result, in part, from the dual role
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of cholesterol as a risk factor for atherosclerosis as well as an agent for delivering nutrients
necessary for cognitive functioning (55). Interestingly, several previous studies have
reported lower levels of serum cholesterol among individuals with depression (56 – 61),
although not all studies have supported this finding (62).
Our observation that higher IMT is associated with poorer neuropsychological functioning is
consistent with previous studies demonstrating an association between greater IMT and
lower performance on tests associated with executive functioning (22,23). Auperin and
colleagues (23) found that higher levels of IMT measured from the common carotid artery
were associated with lower scores on the DSST and COWAT among men, whereas no
consistent relationship was noted in women. Mathiesen and colleagues (22) also found that
common carotid artery stenosis was associated with poorer scores on a range of
neuropsychological tests including the DST, Verbal Paired Associates immediate recall, and
Trail Making Tests, although results were strongest for TMT-B. Notably, these associations
were not significantly attenuated after controlling for white matter hyperintensities measured
by magnetic resonance imaging. In contrast, Knopman and colleagues (44) found that,
although cognitive decline was associated with greater CVRFs, carotid IMT was not
associated with more rapid decline in neuropsychological performance. Several previous
pharmacological interventions have also reported an association between improved vascular
functioning and increases in overall cognitive performance (63,64). Furthermore, Muller and
colleagues (65) recently reported that higher pulse-wave velocity was associated with poorer
performance on cognitive tests assessing processing speed and executive functioning in a
sample of middle-aged and older men.
Results from our study indicate that subclinical levels of atherosclerosis, as measured by
IMT, FMD, and GTN-D, may be associated with increased neuropsychological deficits. The
finding that FMD and GTN-D were significantly associated with executive functioning after
controlling for IMT is not surprising, given that IMT is a structural manifestation of
systemic vascular disease, whereas endothelial and smooth muscle dysfunction precede the
development of IMT (66) and are potentially more sensitive indexes of early atherosclerotic
disease (67). The attenuation of the IMT and executive functioning relationship after
controlling for FMD is therefore understandable, given the shared variance between these
measures and the higher relative sensitivity of FMD. Furthermore, because impaired
vascular function, assessed by FMD and GTN-D, may serve as early markers of a
generalized vascular burden that precedes the development of manifest atherosclerotic
disease, our findings may have important implications for understanding the relationship of
subclinical vascular disease and neuropsychological performance.
The finding that CVRFs are associated with reduced performance on tasks of executive
functioning may be particularly important among individuals with MDD because poorer
executive performance has been associated with an increased risk of relapse among
individuals with vascular depression as well as MDD (68). Previous studies have reported
that executive functioning is the only domain of cognitive functioning shown to differentiate
depressed individuals in remission from healthy controls (69) and has been associated with
nonresponsiveness to pharmacologic treatment in patients with MDD.
Deficits in executive functioning may be the result of damage to the frontal-subcortical
circuits of the brain (14), a series of discrete pathways supporting executive cognitive
functions (70). This region is particularly vulnerable to ischemic injury due to its relatively
long, small-diameter, penetrating branches deriving from the anterior and middle cerebral
arteries (14). Damage in this region could result in multiple deficits in executive functions
because multiple areas of the frontal cortex are perfused by the same “watershed” arteries,
thereby conferring a greater risk of microvascular injury during a state of hypoperfusion.
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Because ischemic damage to this area has been associated with the development of vascular
depression (21), this may have important implications for individuals with MDD.
Furthermore, dysregulation between the prefrontal cortex and the limbic system has been
implicated in the pathogenesis of MDD (71) such that damage to this area might be
associated with decreased regulatory functioning.
This study has several limitations. First, because we used a cross-sectional design, we are
unable to determine if there is a causal relation between CVRFs and neuropsychological
deficits. Second, we used a questionnaire to quantify CVRFs and relied on patient self-
reports to document the presence of coronary heart disease (CHD) and diabetes. It is
possible that other individuals with occult CHD or diabetes might have gone unidentified in
our analysis. Third, the possibility exists that the association between MDD and impaired
neuropsychological performance is due to a common pathway; for example, both may be a
result of hypothalamic-pituitary-adrenal axis dysregulation, which has been associated with
both MDD and neuropsychological deficits (72). Finally, due to the limited range of
depressive symptoms resulting from our inclusion criteria, it is unclear how depression
severity may affect the relationship between neuropsychological performance, CVRFs, and
vascular health among individuals with subclinical levels of depression.
In summary, higher levels of CVRFs were associated with deficits in neuropsychological
functioning among individuals with MDD. Moreover, impaired vascular function predicted
deficits in neurocognitive performance over and above the contribution of higher CVRFs.
Future studies should investigate prospectively the relationship between CVRF, vascular
functioning, and neuropsychological outcomes among individuals with MDD to determine
the natural history of age-related declines in neurocognitive functioning, particularly in the
context of impaired vascular function and CVRFs. Furthermore, the extent to which
neurocognitive function may be improved post MDD treatment needs further study.
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Glossary
CVRF cerebrovascular risk factor
FSRP Framingham Stroke Risk Profile
MDD major depressive disorder
IMT intima medial thickness
GTN glyceryl trinitrate
GTN-D glyceryl trinitrate dilation
FMD flow mediated dilation
HDL high-density lipoprotein
LDL low-density lipoprotein
Ham-D Hamilton Rating Scale for Depression
DSST digit symbol substitution test
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COWAT controlled oral word association test
DST digit span test
CHD coronary heart disease
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Intima medial thickness (IMT) and executive functioning. Adjusted for age, education,
depression, serum cholesterol, and Framingham Stroke Risk Profile levels.
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Flow mediated dilation (FMD) and executive functioning. Adjusted for age, education,
depression, serum cholesterol, and Framingham Stroke Risk Profile levels.
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Flow mediated dilation (FMD) and working memory. Adjusted for age, education,
depression, serum cholesterol, and Framingham Stroke Risk Profile levels.
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Age, mean, years 51.6 7.5
Males, n (%) 48 (24)
Whites, n (%) 134 (68)
College graduate, n (%) 100 (51)
Ham-D, mean 17 4.3
Married, n (%) 75 49
IMT, mean, mm 0.63 0.13
GTN-D, % 20.7 8.23
FMD, % 5.76 4.13
Current smoker, n (%) 32 (16)
Previous smoker (excluding current use), n (%) 65 (38)
SBP, mean, mm Hg 124 18
DBP, mean, mm Hg 79 10
BP-lowering medications, n (%) 47 (23)
Total cholesterol, mean, mg/dl 207 41
LDL total, mean, mg/dl 122 33
HDL total mean, mg/dl 56.9 15.8
Lipid-lowering medications, n (%) 17 (8)
BMI, kg/m2 30.1 7.1
Framingham Risk Profile Score 5.4 3.2
Data are given as number (percentage) unless otherwise indicated.
SD = standard deviation; Ham-D = Hamilton Rating Scale for Depression; IMT = intima medial thickness; GTN-D = glyceryl trinitrate dilation;
FMD = flow mediated dilation; SBP = systolic blood pressure; DBP = diastolic blood pressure; BP = blood pressure; LDL = low-density
lipoprotein; HDL = high-density lipoprotein; BMI = body mass index.

















Ruff 2 and 7 test 231.9 49.5
Digit symbol substitution test 57.6 11.5
Stroop color/word 36.5 9.8
Stroop color 68.7 12.3
Stroop word 95.2 14.8
Trail’s A time (sec) 28.1 10.1
Trail’s B time (sec) 70.3 35.8
Logical memory 24.7 6.5
Verbal recall easy 11.0 1.2
Verbal recall hard 7.1 2.7
DST forward 8.3 2.3
DST backward 6.6 2.1
COWAT 39.5 11.9
Animal naming 19.4 4.9
SD = standard deviation; DST = digit span test; COWAT = controlled oral word association test.
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TABLE 3
Factor Loadings With Individual Testsa
Test Executive Functioning Verbal Recall Working Memory
Ruff total 0.79 0.07 0.17
Digit symbol 0.82 0.32 0.32
Stroop color/word 0.66 0.08 0.54
Stroop color 0.77 −0.07 0.52
Stroop word 0.58 −0.14 0.60
Trail’s A −0.63 −0.07 −0.14
Trail’s B −0.78 −0.16 −0.43
Logical memory 0.16 0.66 −0.01
Verbal recall easy 0.02 0.75 −0.01
Verbal recall hard 0.08 0.83 0.13
Digit forward 0.32 −0.01 0.74
Digit backward 0.37 0.18 0.74
COWAT 0.27 0.15 0.56
Animal naming 0.28 0.30 0.40
COWAT = controlled oral word association test.
a
A minimum loading of 0.40 was required to be retained in the composite variable.
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